Idexx Laboratories reported quarterly EPS of $3.47, topping the Zacks Consensus Estimate of $3.42 by $0.05 and up from $2.96 a year ago. The result indicates solid year-over-year earnings growth and a modest earnings beat. This is positive for IDXX, but the article provides no revenue or guidance details, limiting the likely market impact.
Idexx Laboratories reported quarterly EPS of $3.47, topping the Zacks Consensus Estimate of $3.42 by $0.05 and up from $2.96 a year ago. The result indicates solid year-over-year earnings growth and a modest earnings beat. This is positive for IDXX, but the article provides no revenue or guidance details, limiting the likely market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.34
Ticker Sentiment
